References
- 1. R. L. Siegel, K. D. Miller and A. Jemal, Cancer statistics, CA Cancer J. Clin.68 (2018) 7–30; https://doi.org/10.3322/caac.2144210.3322/caac.21442
- 2. M. Sun, G. Lughezzani, P. Perrotte and P. I. Karakiewicz, Treatment of metastatic renal cell carcinoma, Nat. Rev. Urol.7 (2010) 327–338; https://doi.org/10.1038/nrurol.2010.5710.1038/nrurol.2010.57
- 3. X. Wang, Y. Ren, H. Zhuang, X. Meng, S. Huang, Y. Li, M. Hehir and P. Wang, Decrease of phosphorylated proto-oncogene CREB at Ser 133 site inhibits growth and metastatic activity of renal cell cancer, Expert Opin. Ther. Targets19 (2015) 985–995; https://doi.org/10.1517/14728222.2015.105320810.1517/14728222.2015.1053208
- 4. W. W. An, X. F. Gong, M. W. Wang, S. Tashiro, S. Onodera and T. Ikejima, Norcantharidin induces apoptosis in HeLa cells through caspase, MAPK, and mitochondrial pathways, Acta Pharmacol. Sin.25 (2004) 1502–1508; https://doi.org/10.1016/S0898-6568(03)00096-210.1016/S0898-6568(03)00096-2
- 5. Y. Ren, S. W. Zhang, Z. H. Xie, X. M. Xu, L. L. Chen, Z. G. Lou, G. B. Weng and X. P. Yao, Cantharidin induces G2/M arrest and triggers apoptosis in renal cell carcinoma, Mol. Med. Rep.14 (2016) 5614–5618; https://doi.org/10.3892/mmr.2016.596310.3892/mmr.2016.596327878266
- 6. M. N. Jahnke, S. Hwang, J. L. Griffith and T. Shwayder, Cantharidin for treatment of facial molluscum contagiosum: A retrospective review, J. Am. Acad. Dermatol.78 (2018) 198–200; https://doi.org/10.1016/j.jaad.2017.08.04410.1016/j.jaad.2017.08.04429241785
- 7. F. Massicot, H. Dutertre-Catella, C. Pham-Huy, X. H. Liu, H. T. Duc and J. M. Warnet, In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and nor-cantharidin, Basic Clin. Pharmacol. Toxicol.96 (2005) 26–32; https://doi.org/10.1111/j.1742-7843.2005.pto960104.x10.1111/j.1742-7843.2005.pto960104.x15667592
- 8. S. H. Kok, S. J. Cheng, C. Y. Hong, J. J. Lee, S. K. Lin, Y. S. Kuo, C. P. Chiang and M. Y. Kuo, Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio, Cancer Lett.217 (2005) 43–52; https://doi.org/10.1016/j.canlet.2004.07.04510.1016/j.canlet.2004.07.04515596295
- 9. C. H. Hsia, W. J. Lu, K. H. Lin, D. S. Chou, P. Geraldine, T. Jayakuma, N. C. Chang and J. R. Sheu, Norcantharidin, a clinical used chemotherapeutic agent, acts as a powerful inhibitor by interfering with fibrinogen-integrin alphaIIb beta3 binding in human platelets, J. Cell Mol. Med.22 (2018) 2142–2152; https://doi.org/10.1111/jcmm.1348810.1111/jcmm.13488586711629369482
- 10. Y. Li, Q. Chen, F. Y. Liu, Y. M. Peng, T. Hou, S. B. Duan, J. Li, J. H. Luo, L. Sun and G. H. Ling, Norcantharidin attenuates tubulointerstitial fibrosis in rat models with diabetic nephropathy, Ren. Fail.33 (2011) 233–241; https://doi.org/10.3109/0886022X.2011.55330510.3109/0886022X.2011.55330521332346
- 11. T. Yu, F. Hou, M. Liu, L. Zhou, D. Li, J. Liu, Z. Fan and Q. Li, Norcantharidin anti-angiogenesis activity possibly through an endothelial cell pathway in human colorectal cancer, Asian Pac. J. Cancer Prev.13 (2012) 499–503; https://doi.org/10.7314/APJCP.2012.13.2.49910.7314/APJCP.2012.13.2.49922524814
- 12. H. Lv, Y. Li, H. Du, J. Fang, X. Song and J. Zhang, The synthetic compound norcantharidin induced apoptosis in mantle cell lymphoma in vivo and in vitro through the PI3K-Akt-NF- kappa B signaling pathway, Evid. Based Complement Alternat. Med.2013 (2013) 461487; https://doi.org/10.1155/2013/46148710.1155/2013/461487372298023935664
- 13. Q. Y. Zhang, X. Q. Yue, Y. P. Jiang, T. Han and H. L. Xin, FAM46C is critical for the anti-proliferation and pro-apoptotic effects of norcantharidin in hepatocellular carcinoma cells, Sci. Rep.7 (2017) 396; https://doi.org/10.1038/s41598-017-00313-610.1038/s41598-017-00313-6542825828341836
- 14. P. Y. Yang, M. F. Chen, Y. H. Kao, D. N. Hu, F. R. Chang and Y. C. Wu, Norcantharidin induces apoptosis of breast cancer cells: involvement of activities of mitogen activated protein kinases and signal transducers and activators of transcription, Toxicol. In Vitro25 (2011) 699–707; https://doi.org/10.1016/j.tiv.2011.01.01110.1016/j.tiv.2011.01.01121266192
- 15. C. L. Lin, C. M. Chen, C. L. Lin, C. W. Cheng, C. H. Lee and Y. H. Hsieh, Norcantharidin induces mitochondrial-dependent apoptosis through Mcl-1 inhibition in human prostate cancer cells, Biochim. Biophys. Acta1864 (2017) 1867–1876; https://doi.org/10.1016/j.bbamcr.2017.07.01510.1016/j.bbamcr.2017.07.01528760656
- 16. Z. Wang, D. You, M. Lu, Y. He and S. Yan, Inhibitory effect of norcantharidin on melanoma tumor growth and vasculogenic mimicry by suppressing MMP-2 expression, Oncol. Lett.13 (2017) 1660–1664; https://doi.org/10.3892/ol.2017.562210.3892/ol.2017.5622540326728454306
- 17. M. Y. Huang, L. L. Zhang, J. Ding and J. J. Lu, Anticancer drug discovery from Chinese medicinal herbs, Chin. Med.13 (2018) 35; https://doi.org/10.1186/s13020-018-0192-y10.1186/s13020-018-0192-y603119429997684
- 18. A. A. Nagle, F. F. Gan, G. Jones, C. L. So, G. Wells and E. H. Chew, Induction of tumor cell death through targeting tubulin and evoking dysregulation of cell cycle regulatory proteins by multi-functional cinnamaldehydes, PLoS One7 (2012) e50125; https://doi.org/10.1371/journal.pone.005012510.1371/journal.pone.0050125350376123185555
- 19. S. C. Biswas, P. Sanphui, N. Chatterjee, S. Kemeny and L. A. Greene, Cdc25A phosphatase: a key cell cycle protein that regulates neuron death in disease and development, Cell Death Dis.8 (2017) e2692; https://doi.org/10.1038/cddis.2017.11510.1038/cddis.2017.115538652128333146
- 20. J. Wang and Y. F. Jiang, Natural compounds as anticancer agents: Experimental evidence, World J. Exp. Med.2 (2012) 45–57; https://doi.org/10.5493/wjem.v2.i3.4510.5493/wjem.v2.i3.45390558324520533
- 21. N. Bailon-Moscoso, G. Cevallos-Solorzano, J. C. Romero-Benavides and M. I. Orellana, Natural compounds as modulators of cell cycle arrest: Application for anticancer chemotherapies, Curr. Genomics.18 (2017) 106–131; https://doi.org/10.2174/138920291766616080812564510.2174/1389202917666160808125645534533328367072
- 22. M. Brentnall, L. Rodriguez-Menocal, R. L. De Guevara, E. Cepero and L. H. Boise, Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis, BMC Cell Biol.14 (2013) 32; https://doi.org/10.1186/1471-2121-14-3210.1186/1471-2121-14-32371024623834359
- 23. J. Kale, E. J. Osterlund and D. W. Andrews, BCL-2 family proteins: changing partners in the dance towards death, Cell Death Differ.25 (2018) 65–80; https://doi.org/10.1038/cdd.2017.18610.1038/cdd.2017.186572954029149100
- 24. W. W. Chu, X. Y. He, A. L. Yan, S. W. Wang, S. Li, S. Nian, Y. L. Wang and F. L. Liang, Ischemic postconditioning lightening ischemia/reperfusion apoptosis of rats via mitochondria pathway, Eur. Rev. Med. Pharmacol. Sci.23 (2019) 6307–6314; https://doi.org/10.26355/eurrev_201907_18453
- 25. H. K. An, K. M. Chung, H. Park, J. Hong, J. E. Gim, H. Choi, Y. W. Lee, J. Choi, J. Y. Mun and S. W. Yu, CASP9 (caspase 9) is essential for autophagosome maturation through regulation of mitochondrial homeostasis, Autophagy (2019) 1–20; https://doi.org/10.1080/15548627.2019.169539810.1080/15548627.2019.1695398838660831818185
- 26. C. L. Cusack, V. Swahari, W. H. Henley, J. M. Ramsey and M. Deshmukh, Distinct pathways mediate axon degeneration during apoptosis and axon-specific pruning, Nat. Commun.4 (2013) 1876; https://doi.org/10.1038/ncomms291010.1038/ncomms2910418306123695670
- 27. G. Pearson, F. Robinson, T. Beers Gibson, B. E. Xu, M. Karandikar, K. Berman and M. H. Cobb, Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions, Endocr. Rev.22 (2001) 153–183; https://doi.org/10.1210/edrv.22.2.042810.1210/edrv.22.2.042811294822
- 28. Y. Sun, W. Z. Liu, T. Liu, X. Feng, N. Yang and H. F. Zhou, Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis, J. Recept. Signal Transduct. Res.35 (2015) 600–604; https://doi.org/10.3109/10799893.2015.103041210.3109/10799893.2015.103041226096166
- 29. T. Chen and Y. S. Wong, Selenocystine induces S-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells by modulating ERK and Akt phosphorylation, J. Agric. Food Chem.56 (2008) 10574–10581; https://doi.org/10.1021/jf802125t10.1021/jf802125t18959417
- 30. W. Liu, R. Ning, R. N. Chen, X. F. Huang, Q. S. Dai, J. H. Hu, Y. W. Wang, L. L. Wu, J. Xiong, G. Hu, Q. L. Guo, J. Yang and H. Wang, Aspafilioside B induces G2/M cell cycle arrest and apoptosis by up-regulating H-Ras and N-Ras via ERK and p38 MAPK signaling pathways in human hepatoma HepG2 cells, Mol. Carcinog.55 (2016) 440–457; https://doi.org/10.1002/mc.2229310.1002/mc.2229325683703
- 31. Y. Tsuchiya, S. Murai and S. Yamashita, Dual inhibition of Cdc2 protein kinase activation during apoptosis in Xenopus egg extracts, FEBS J.282 (2015) 1256–1270; https://doi.org/10.1111/febs.1321710.1111/febs.1321725631627
- 32. W. J. Sun, H. Huang, B. He, D. H. Hu, P. H. Li, Y. J. Yu, X. H. Zhou, Z. Lv, L. Zhou, T. Y. Hu, Z. C. Yao, M. D. Lu, X. Shen and Z. Q. Zheng, Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepato-cellular carcinoma cells, Biochem. Pharmacol.127 (2017) 90–100; https://doi.org/10.1016/j.bcp.2016.12.00810.1016/j.bcp.2016.12.00828012958
- 33. X. Grana and E. P. Reddy, Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs), Oncogene11 (1995) 211–219.
- 34. N. Kaushal and M. P. Bansal, Inhibition of CDC2/Cyclin B1 in response to selenium-induced oxidative stress during spermatogenesis: potential role of Cdc25c and p21, Mol. Cell Biochem.298 (2007) 139–150; https://doi.org/10.1007/s11010-006-9360-y10.1007/s11010-006-9360-y17160696
- 35. Y. C. Cho, J. E. Park, B. C. Park, J. H. Kim, D. G. Jeong, S. G. Park and S. Cho, Cell cycle-dependent Cdc25C phosphatase determines cell survival by regulating apoptosis signal-regulating kinase 1, Cell Death Differ.22 (2015) 1605–1617; https://doi.org/10.1038/cdd.2015.210.1038/cdd.2015.2456378625633196
- 36. Y. S. Sun, L. X. Lv, Z. Zhao, X. He, L. You, J. K. Liu and Y. Q. Li, Cordycepol C induces caspase-independent apoptosis in human hepatocellular carcinoma HepG2 cells, Biol. Pharm. Bull.37 (2014) 608–617; https://doi.org/10.1248/bpb.b13-0087710.1248/bpb.b13-0087724694607
- 37. M. Gaestel, MAPK-activated protein kinases (MKs): Novel insights and challenges, Front Cell Dev. Biol.3 (2015) 88; https://doi.org/10.3389/fcell.2015.0008810.3389/fcell.2015.00088470522126779481
- 38. Z. Han, B. Li, J. Wang, X. Zhang, Z. Li, L. Dai, M. Cao and J. Jiang, Norcantharidin inhibits SK-NSH neuroblastoma cell growth by induction of autophagy and apoptosis, Technol. Cancer Res. Treat.16 (2017) 33–44; https://doi.org/10.1177/153303461562458310.1177/1533034615624583561611226755751
- 39. Y. N. Chen, C. C. Cheng, J. C. Chen, W. Tsauer and S. L. Hsu, Norcantharidin-induced apoptosis is via the extracellular signal-regulated kinase and c-Jun-NH2-terminal kinase signaling pathways in human hepatoma HepG2 cells, Br. J. Pharmacol.140 (2003) 461–470; https://doi.org/10.1038/sj.bjp.070546110.1038/sj.bjp.0705461157405212970086